Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Date:2/24/2009

AMSTERDAM, the Netherlands, February 24 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year of 2008.

    Highlights

    - Extra clinical trial in LPL deficiency causes a delay of the announced
      filing date for lead product GlyberaTM which is now expected H2 2009
    - Positive clinical data on GlyberaTM
    - CEO Ronald Lorijn resigned for personal reasons
    - Start of clinical multicenter Hemophilia B trial in 2009
    - Start development of treatments for Duchenne Muscular Dystrophy and
      Parkinson's disease
    - Scale up of unique and proprietary production platform to fully support
      worldwide commercial supply for current products
    - Independent supervisory board with three new members bringing extensive
      knowledge and experience.
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 34.2 million at December 31, 2008

Results comparison

AMT's operating loss increased to EUR 18.8 million for 2008, from EUR 14.7 million for 2007. The difference is primarily due to the increase of research & development costs to EUR 13.1 million, from EUR 9.8 million in 2007. This increase is particularly related to the development work on the company's lead product, GlyberaTM, increased staffing for this and other programs and an increase in research collaborations. General and administrative costs increased to EUR 5.9 million, from EUR 5.0 million in 2007, primarily as a result of increased employee costs and increased advisor's fees. The net loss for 2008 was EUR 16.9 million, as compared to a net loss of EUR 14.9 million for 2007. As of December 31, 2008, AMT had cash and cash equivalents of EUR 34.2 million, compared to EUR 51.3 million at December 31, 2007. The cash burn for the year amounted to EURO 17.2 million which i
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
4. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
10. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
11. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... 2014 According to a new market report ... orthobiologics market was valued at USD 3,754.6 million in 2012 ... in 2019at a CAGR of 5.9% from 2013 to 2019. ... above is afflicted by bone and joint disorders, and this ... This has and will continue to increase the demand for ...
(Date:8/29/2014)... August 29, 2014 Local veterinarian, Dr. ... Hospital are seeking candidates to participate in an investigational ... The ultimate goal of this study is to ... into one or two arthritically affected joints can help ... , Candidates for the current investigational study must be ...
(Date:8/29/2014)... A major challenge before new biotechnology start-up ... of Boston-Cambridge, is gaining visibility that can lead to ... Director of Boston’s Adult Stem Cell Technology Center, LLC ... of his company an important priority since he started ... a social media marketing campaign launched earlier ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... product ideas to market, RESEARCH TRIANGLE PARK, N.C., ... to $1 million in loans under,a program unveiled this ... loans are part of an expanded program funded by ... give early-stage,companies a boost before they become competitive for ...
... Nargis, a category 3 tropical storm that struck the low-lying and ... Agriculture Service (FAS) of the U.S. Department of Agriculture (USDA) began ... damaged agricultural areas to accompany its commodity intelligence reports. , ... ...
... July 9 Brinks Hofer Gilson & Lione, one of ... opening,of a new office in the Raleigh/Durham, North Carolina area ... T. Elliott, who will be,based in the Raleigh office. Mr. ... the firm as partners. The office will officially,be open for ...
Cached Biology Technology:N.C. Biotech Center Launches Larger Loans 2Myanmar's Cyclone-Damaged Rice Production Regions Monitored with GIS 2Myanmar's Cyclone-Damaged Rice Production Regions Monitored with GIS 3Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 2Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 3
(Date:8/31/2014)... past several decades, malaria diagnosis has changed very little. After ... the blood across a glass slide, stains it with a ... parasite, which causes the disease. This approach gives an accurate ... an important measure of disease severity but is not ... research team from the Singapore-MIT Alliance for Research and Technology ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... climatic shifts over the last 120,000 years may ... team of researchers led by City College of ... new biodiversity metric called "phylogeographic endemism." , It ... within species is restricted in geographical space. , ... 14 other researchers from institutions in Brazil, Australia ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3Factor in naked mole rat's cells enhances protein integrity 2CCNY team defines new biodiversity metric 2
... , Simultaneous targeting of two different molecules in cancer ... and stop metastasis, scientists at the University of California, ... effectiveness of combination treatments that include drugs like Avastin. ... a type of cancer known as neuroendocrine pancreatic tumors, ...
... German . Hydrofluorocarbons (HFCs), which have been ... CFCs, are also climatically very active and many are also ... international team of researchers recommends that the most potent of ... side effect of the Montreal Protocol for the global climate. ...
... affects the air, it also seeps under the asphalt and ... chemist at the University of the Basque Country (UPV/EHU), has ... impact of the metals emitted by cars. Likewise, he has ... and for this purpose has taken samples from roadsides in ...
Cached Biology News:Cancer therapy more potent when it hits 2 targets 2Cancer therapy more potent when it hits 2 targets 3Protecting the climate by reducing fluorinated greenhouse gas emissions 2Protecting the climate by reducing fluorinated greenhouse gas emissions 3Car tracks beyond the asphalt 2Car tracks beyond the asphalt 3
... 1) Persistent Analysis Environment 2) Dot ... etc. 3) Software Compensation 4) Cell ... Kinetics Platform 7) Intelligent batch generation of ... smoothing 9) Single drag-and-drop operations to perform ...
... Todays advanced protein cross-linking techniques are defined ... Dr. Shan S. Wong. This valuable hardcover ... schemes and current application references. More than ... protein cross-linking and conjugate preparation from ...
Schneider's Drosophila - Insect medium...
... easy operation of a wide range of ... software is fully secure and compliant with ... regulations, and compatible with user-created macros for ... use in high-level research and development as ...
Biology Products: